Within the intersection DEGs of the two datasets, we observed that LOXL2 was consistently upregulated in CRPC cell lines, as determined in the GEO dataset, and radioresistant prostate cancer samples, as determined in the TCGA dataset. Here, LOXL2 is linked to prostate carcinoma.